Vor Biopharma (VOR) Set to Announce Quarterly Earnings on Monday

Vor Biopharma (NYSE:VOR) is set to issue its quarterly earnings data on Monday, April 29th.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.10. On average, analysts expect Vor Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vor Biopharma Stock Performance

Shares of NYSE VOR opened at $1.69 on Friday. The stock has a market cap of $115.29 million, a price-to-earnings ratio of -0.96 and a beta of -0.36. The business has a 50 day simple moving average of $2.01 and a 200 day simple moving average of $2.11. Vor Biopharma has a 52 week low of $1.62 and a 52 week high of $5.70.

Analyst Upgrades and Downgrades

VOR has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating and issued a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research note on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research report on Thursday, March 21st. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a research report on Tuesday, April 23rd. Stifel Nicolaus decreased their target price on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research report on Friday, March 22nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.50.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.